The Value of Systematic Versus Targeted Sampling in Prostate Cancer Detection and the Identification of Adverse Pathologic Features

The American Journal of Surgical Pathology 2026

View at publisher
Authors: Ngoc-Nhu Jennifer Nguyen, Vincent F. Castillo, Ekaterina Olkhov‐Mitsel, Rola Saleeb, Theodorus van der Kwast, Michelle R. Downes
DOI: 10.1097/pas.0000000000002564
Cited by: 1
References: 40

Abstract

The value of systematic biopsy (SBx) versus targeted biopsy (TBx) in the detection of prostate cancer and its adverse pathologic (AP) features was compared using a multi-institutional cohort of combined prostate biopsies with treatment-naive prostatic adenocarcinoma (N=1402, time period 2022 to 2025). Analyzed features included the highest International Society of Urological Pathology grade group (GG), clinically insignificant prostate cancer (CIPC, defined as GG1), clinically significant prostate cancer (CSPC, defined as GG ≥2), and AP (overall GG ≥3, cribriform/intraductal carcinoma, ductal features, extraprostatic extension, and/or seminal vesicle invasion). Compared with SBx, TBx more frequently had the highest GG cancer (81.2% vs. 58.8%, P

Fields of Study & Subjects

Prostate Cancer Diagnosis and Treatment Prostate Cancer Treatment and Research Urologic and reproductive health conditions

Publication details

Journal / source
The American Journal of Surgical Pathology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
50
Issue
8
Pages
972–980
Publication date
11 May 2026
Language
EN